Guided by courage, curiosity, and a forward-thinking vision, we embrace bold ideas and innovative solutions.

Sean Meehan, Chief Operating Officer (COO) and founding member of Exvade Bioscience, has been an instrumental force in the development and clinical translation of the TMD. With a robust background in mechanical and biomedical engineering, combined with specialized expertise in nanomaterials, Mr. Meehan has played a pivotal role in advancing both the scientific and clinical dimensions of the device. His leadership has been crucial in refining the device’s effectiveness while simultaneously guiding its transition from the laboratory to clinical settings. Under his direction, Exvade has made significant strides in both technological innovation and real-world medical application and its ongoing mission to revolutionize the field of cancer treatment.

Dr. Barun Brahma, a neurosurgeon based in Atlanta, has made significant contributions to the field of brain and spinal cord disorders, particularly in the treatment of brain tumors. With extensive training and experience in both clinical practice and surgical innovation, Dr. Brahma is renowned for his expertise in treating complex neurological conditions in children. As a key member of the team at Exvade Bioscience, he has been instrumental in providing critical insights from a clinical perspective, ensuring that the TMD’s development aligns with real-world medical needs. His deep understanding of pediatric neurosurgery has been invaluable in guiding the device’s clinical applications, while his collaborative efforts have also helped shape its design and implementation strategies.

“Jack Griffis is a seasoned professional with 33 years of experience in the medical device industry and a Master of Science in Mechanical Engineering from the Georgia Institute of Technology. Mr. Griffis has received seven national design excellence awards for his work in a wide variety of biomedical technologies, including 60 patents issued through the USPTO. Mr. Griffis  was inducted into the National Academy of Inventors in 2014 and continues to serve as a mentor through the NAI outreach program via the Global Academic Inventors Network. Currently, he serves as the Chief Technology Office for Kessel Medical; an ISO 13485:2016 certified medical device manufacturer based in Vero Beach, Florida. Mr. Griffis has supported the design and development of the Tumor Monorail device since 2015 and is one of the named inventors on the most recent patent.”

Jim Pokorney serves as a regulatory and product development consultant for Exvade Bioscience, bringing extensive experience in designing and developing medical devices. With expertise in areas like catheters, stents, and embolic filters, Jim has provided valuable guidance in the design and regulatory aspects of the TMD. His insights have helped ensure the device meets regulatory standards and is optimized for manufacturability as it progresses toward commercialization.

Don Griffin is an experienced engineering leader in medical device development and operations, with expertise across a wide range of areas. At Exvade Bioscience, Don has played a key role in the development of the TMD, applying his extensive experience in project management, validation, and cost reduction to ensure the device meets regulatory standards and is cost-effective. His support in operations and design for manufacturing has been instrumental in advancing the TMD from concept to clinical application, driving Exvade’s mission to deliver innovative healthcare solutions.

Dr. Nassir Mokarram has established himself as a pioneer in the field of immunomodulatory biomaterials for neural tissue engineering. With a distinguished background in bioengineering, materials science, and immunoengineering, combined with invaluable experience from the Biodesign Innovation Fellowship at Stanford University, Dr. Mokarram has positioned himself at the forefront of innovation in medical technology. As the Chief Executive Officer of Exvade Bioscience, he has played a pivotal role in the development and clinical translation of the TMD, providing strategic leadership in both the technical evolution of the device and its go-to-market strategy. In addition to overseeing product development, Dr. Mokarram has been instrumental in managing the intellectual property (IP) process and spearheading fundraising efforts, further solidifying his leadership and vision in advancing the company’s mission.

‍

‍

Tejas Mazmudar serves as a regulatory advisor for Exvade Bioscience, contributing his nearly two decades of experience in medical device development and regulatory strategy. Leveraging his expertise in clinical strategy and regulatory compliance, Tejas has played a key role in guiding the development of the TMD, ensuring it meets all necessary regulatory requirements. His background with Class II and III devices, particularly in cardiology and gynecology, has been invaluable in navigating FDA submissions, clinical validation, and quality assurance. Tejas continues to provide strategic insights, helping Exvade successfully advance the TMD toward commercialization.